secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-036122
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q2 cash $60.3M; CRDF-004 readout expected 2H 2024
------------------------------------------------------------------

- Cash and equivalents $60.3M as of June 30, 2024; runway to Q3 2025.
- Net cash used in ops $9.2M in Q2 2024 vs $7.1M in Q2 2023.
- Total operating expenses $12.7M for Q2 2024, up $0.4M YoY.
- CRDF-004 trial for first-line RAS-mutated mCRC data readout expected in 2H 2024.
- Preclinical data published on onvansertib + olaparib in olaparib-resistant ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024036122/0001628280-24-036122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024036122/crdf-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer